Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Iovance Biotherapeutics Inc (IOVA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Iovance Biotherapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
11.98 +0.34    +2.96%
14:46:06 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 2,210,721
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 11.72 - 12.11
Iovance Biotherapeutics 11.98 +0.34 +2.96%

Iovance Biotherapeutics Inc Company Profile

 
Get an in-depth profile of Iovance Biotherapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

557

Equity Type

ORD

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Contact Information

Address 825 Industrial Road Suite 400
San Carlos, 94070
United States
Phone 650 260 7120
Fax -
Web www.iovance.com

Top Executives

Name Age Since Title
Cassian Yee - - Member of Scientific Advisory Board
Patrick Hwu - - Member of Scientific Advisory Board
Jeffrey S. Weber - - Member of Scientific Advisory Board
Mario Sznol 65 - Member of Scientific Advisory Board
Daniel J. Powell - - Member of Scientific Advisory Board
Iain D. Dukes 65 2016 Independent Chairman of the Board
Wayne P. Rothbaum 55 2016 Independent Director
Athena Maria Countouriotis 51 2019 Independent Director
James J. Mule - - Member of Scientific Advisory Board
Wendy L. Yarno 68 2023 Independent Director
Merrill A. McPeak 87 2011 Independent Director
Ryan D. Maynard 54 2015 Independent Director
Michael Weiser 60 2018 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

IOVA Comments

Write your thoughts about Iovance Biotherapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Trader UJ
Trader UJ Feb 21, 2024 12:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
7 to 15... sell half to secure initial investment and keep 1/2 freebie shares or hold all.... hmmmm... this is the best problem to have to decide...
Reply
4 0
Report
Almeem Alqubaisi
Almeem Alqubaisi Jan 07, 2024 4:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
✋✋✋
Reply
0 0
Report
burak ozsoy
burak ozsoy Oct 11, 2023 10:58AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What hapeneddddd
Reply
0 0
Report
Ömer Akın
Ömer Akın Oct 09, 2023 11:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What down ?
Reply
0 0
Report
Brandon Wallace
Brandon Wallace May 21, 2023 6:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why no comments
Reply
2 0
Report
Mount Kilamanjaro
Mount Kilamanjaro Jul 14, 2022 3:30PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Scam
Reply
0 1
Report
Nelson Neagoe
Nelson Neagoe Jun 02, 2022 11:31PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy.
Reply
2 0
Report
Jamie Kent
Jamie Kent Jun 07, 2021 9:42PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Nice move up today. Now up 22.5% from the big dip on May 19th
Reply
1 0
Report
Viren Patel
Viren Patel May 19, 2021 8:40PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Its time to buy ?
Reply
2 0
Report
Jamie Kent
Jamie Kent May 19, 2021 8:40PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
40% is a pretty big discount, but there was a delay and CEO change. I think in time it can have good upside. Most still have targets in the $40-$50 range after being downgraded following recent news. This seems like an overreaction.
Reply
0 0
Report
Viren Patel
Viren Patel May 19, 2021 8:40PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thank you. it's up today. hold or sell ?
Reply
0 0
Report
Viren Patel
Viren Patel May 19, 2021 8:40PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's best price to sell ?
Reply
0 0
Report
Jamie Kent
Jamie Kent May 19, 2021 8:40PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is a longer play for me... months or years; after their cancer treatment is approved and on the market.
Reply
1 0
Report
Sharon Martin
Sharon Martin May 19, 2021 3:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Just bought a little. Hope this is a big dip and not a big mistake.
Reply
4 0
Report
Jamie Kent
Jamie Kent May 19, 2021 3:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Me too. Looks like potential for a lot of upside once the new CEO is settled in and they get back on track with their skin cancer treatment. 40% seems like a big over reaction.
Reply
1 0
Report
Eric Kennedy
Eric Kennedy May 19, 2021 3:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
created a position too. if it goes down, I'll add. this will come back some day
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email